Related Experiment Video

Updated: Jul 18, 2026

Combining Double Fluorescence In Situ Hybridization with Immunolabelling for Detection of the Expression of Three Genes in Mouse Brain Sections
09:23

Combining Double Fluorescence In Situ Hybridization with Immunolabelling for Detection of the Expression of Three Genes in Mouse Brain Sections

Published on: March 26, 2016

Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease

P Leone1, C G Janson, S J McPhee

  • 1CNS Gene Therapy Center, Department of Neurosurgery, Thomas Jefferson University, Philadelphia, PA 19107, USA. Paola.Leone@mail.tju.edu

Current Opinion in Molecular Therapeutics
|November 21, 2001
PubMed

Insights

Canavan disease (CD) is a fatal neurogenetic disorder caused by ASPA gene mutations. Gene therapy using novel liposome-polymer-DNA complexes and adeno-associated virus vectors shows promise for treating this leukodystrophy.

Area of Science:

  • Neurogenetics
  • Molecular Biology
  • Biochemistry

Background:

  • Canavan disease (CD) is a fatal autosomal recessive leukodystrophy characterized by spongiform degeneration of the brain.
  • CD results from mutations in the aspartoacylase (ASPA) gene, leading to a loss of enzyme activity.
  • Current treatment options for CD are limited, with the disease being uniformly fatal.

Purpose of the Study:

  • To review the etiology and potential treatments for Canavan disease.
  • To discuss advancements in gene therapy strategies for CD.
  • To evaluate novel gene delivery systems, including liposome-polymer-DNA complexes and adeno-associated virus vectors.

Main Methods:

  • Review of recent scientific literature on Canavan disease.
  • Discussion of viral gene delivery systems (adeno-associated virus - AAV).
  • Discussion of non-viral gene delivery systems (liposome-polymer-DNA - LPD complex).

Main Results:

  • Canavan disease is a severe neurogenetic disorder with no effective treatments.
  • Gene therapy presents a potential therapeutic avenue for CD.
  • Novel LPD complexes and AAV vectors represent promising advancements in gene delivery for CD.

Conclusions:

  • Gene therapy holds significant potential for treating Canavan disease.
  • Further research into LPD complexes and AAV vectors is warranted for CD treatment.
  • Advancements in gene delivery technologies offer hope for managing this fatal leukodystrophy.

More Related Videos

In Vivo Gene Transfer to Schwann Cells in the Rodent Sciatic Nerve by Electroporation05:40

In Vivo Gene Transfer to Schwann Cells in the Rodent Sciatic Nerve by Electroporation

Published on: September 8, 2016

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer09:39

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using In Utero Electroporation-based Gene Transfer

Published on: June 9, 2018

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...